• Reuters

  • SHARE

Bangladesh’s drug regulatory authority on Sunday issued a ban on sales of popular heartburn drug ranitidine while it investigates a potential cancer-causing substance in the drug.

The move comes after the U.S. Food and Drug Administration (FDA) warned that some of the pills contained small amounts N-nitrosodimethylamine (NDMA), which the regulator says is a “probable human carcinogen.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW